以嶺藥業(002603.SZ):連花清瘟膠囊(顆粒)被列入《流行性感冒診療方案(2019年版)》
格隆匯11月14日丨以嶺藥業(002603.SZ)公佈,近日,國家衞生健康委辦公廳、國家中醫藥管理局辦公室聯合發佈了《流行性感冒診療方案(2019年版)》。公司研發生產的專利藥物——連花清瘟膠囊(顆粒)均被列入其中,成為《流行性感冒診療方案(2019年版)》推薦用藥。
連花清瘟膠囊(顆粒)為公司的主導產品、國家基本藥物目錄和國家醫保目錄(甲類)品種,主要用於感冒、流感相關疾病的治療。連花清瘟膠囊先後多次被國家衞生健康委、國家中醫藥管理局列入感冒、流感相關疾病診療方案。2015年12月,連花清瘟膠囊獲美國FDA批准開展二期臨牀研究,成為全球第一個獲美國FDA批准開展臨牀研究的治感冒抗流感複方中藥。
2019年前三季度,公司連花清瘟產品實現營業收入14.15億元,佔公司營業收入的32.54%。
公司預計此次《流行性感冒診療方案(2019年版)》的發佈將對連花清瘟膠囊(顆粒)的市場推廣產生積極影響,但產生影響的時間和影響程度存在一定不確定性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.